71 related articles for article (PubMed ID: 16899784)
21. Methodologic issues in the validation of putative biomarkers and surrogate endpoints in treatment evaluation for systemic lupus erythematosus.
Liang MH; Simard JF; Costenbader K; Dore BT; Ward M; Fortin PR; Illei GG; Manzi S; Mittleman B; Buyon J; Gupta S; Abrahamowicz M
Endocr Metab Immune Disord Drug Targets; 2009 Mar; 9(1):108-12. PubMed ID: 19275685
[TBL] [Abstract][Full Text] [Related]
22. Polypharmacy, inappropriate prescribing and adverse drug reactions in Austria.
Müller M
Wien Klin Wochenschr; 2008; 120(23-24):713-4. PubMed ID: 19122980
[No Abstract] [Full Text] [Related]
23. Translational research: forging a new cultural identity.
Coller BS
Mt Sinai J Med; 2008 Oct; 75(5):478-87. PubMed ID: 18828172
[TBL] [Abstract][Full Text] [Related]
24. Response to AMA's Council on Ethical and Judicial Affairs draft report on "Ethical guidance for physicians and the profession with respect to industry support for professional education in medicine".
Stossel TP
Medscape J Med; 2008 Jun; 10(6):137. PubMed ID: 18679553
[No Abstract] [Full Text] [Related]
25. Gap in publication of comparative information on new medicines.
van Luijn JC; Stolk P; Gribnau FW; Leufkens HG
Br J Clin Pharmacol; 2008 May; 65(5):716-22. PubMed ID: 18294324
[TBL] [Abstract][Full Text] [Related]
26. Ex Vivo Metrics, a preclinical tool in new drug development.
Curtis CG; Bilyard K; Stephenson H
J Transl Med; 2008 Jan; 6():5. PubMed ID: 18215298
[TBL] [Abstract][Full Text] [Related]
27. How can we regulate medicines better?
Garattini S; Bertele' V
BMJ; 2007 Oct; 335(7624):803-5. PubMed ID: 17947785
[TBL] [Abstract][Full Text] [Related]
28. Food and Drug Administration.
Horton LR
BMJ; 2007 Jan; 334(7584):55-6. PubMed ID: 17218671
[TBL] [Abstract][Full Text] [Related]
29. Drug discovery in jeopardy.
Cuatrecasas P
J Clin Invest; 2006 Nov; 116(11):2837-42. PubMed ID: 17080187
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluations in the canadian common drug review.
Laupacis A
Pharmacoeconomics; 2006; 24(11):1157-62. PubMed ID: 17067199
[TBL] [Abstract][Full Text] [Related]
31. Improving how we evaluate the toxicity of approved drugs.
Reidenberg MM
Clin Pharmacol Ther; 2006 Jul; 80(1):1-6. PubMed ID: 16815311
[No Abstract] [Full Text] [Related]
32. Dermatology clinical trials and drug development.
Ehrenberger HE; Joshi TG
Dermatol Nurs; 2003 Oct; 15(5):428-34. PubMed ID: 14619320
[No Abstract] [Full Text] [Related]
33. A proposal for radical changes in the drug-approval process.
Wood AJ
N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784
[No Abstract] [Full Text] [Related]
34. [FDA's new drug approval system].
Ishii A
Gan To Kagaku Ryoho; 1995 Aug; 22(9):1146-51. PubMed ID: 7661565
[No Abstract] [Full Text] [Related]
35. Drug safety on trial.
Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
[No Abstract] [Full Text] [Related]
36. Drug safety special: the safety catch.
Wadman M
Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
